High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia

Richard F. Schlenk; U. Germing; F. Hartmann; A. Glasmacher; I. T. Fischer; F. del Valle y Fuentes; K. Götze; H. Pralle; C. Nerl; H. Salwender; W. Grimminger; A. Petzer; M. Hensel; A. Benner; L. Zick; K. Döhner; S. Fröhling; H. Döhner

doi:10.1038/sj.leu.2403766

High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia

Richard F. Schlenk
, U. Germing
, F. Hartmann
, A. Glasmacher
, I. T. Fischer
, F. del Valle y Fuentes
, K. Götze
, H. Pralle
, C. Nerl
, H. Salwender
, W. Grimminger
, A. Petzer
, M. Hensel
, A. Benner
, L. Zick
, K. Döhner
, S. Fröhling
, H. Döhner

Department of Internal Medicine III - Hematology and Medical Oncology

University Medical Center Ulm and Center of Excellence 'Metabolic Disorders'
Heinrich-Heine-University
Saarland University Medical Center
University of Bonn
Städtisches Klinikum Karlsruhe
Städtisches Klinikum
Justus-Liebig-Universität Gießen
City Hospital Munich-Schwabing
Asklepios Klinik Hamburg
Klinikum Stuttgart
University of Innsbruck
Heidelberg University
German Cancer Research Center

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL). Patients (age 16-60 years) received induction therapy according to the AIDA protocol (all-trans retinoic acid, idarubicin) followed by one cycle of ICE (idarubicin, cytarabine, etoposide) and two cycles of HAM (cytarabine 3 g/m² q12h, days 1-3; mitoxantrone 10 mg/m², days 2 and 3). From 1995 to 2003, 82 patients were enrolled. In total, 72 patients (88%) achieved a complete remission, and 10 patients (12%) died from early/hypoplastic death (ED/HD). A total of 71 patients received at least one cycle of HAM. Relapse-free survival (RFS) and overall survival (OS) after 46 months were 83 and 82%, respectively. White blood cell count above 10.0 × 10⁹/l at diagnosis and additional chromosomal aberrations were unfavorable prognostic markers for OS, whereas no prognostic markers for RFS were identified including FLT3 mutations. In conclusion, high-dose cytarabine in consolidation therapy for patients with newly diagnosed APL is an effective treatment approach.

Original language	English
Pages (from-to)	978-983
Number of pages	6
Journal	Leukemia
Volume	19
Issue number	6
DOIs	https://doi.org/10.1038/sj.leu.2403766
State	Published - Jun 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Activating FLT3 mutations
Acute promyelocytic leukemia
Additional chromosomal aberrations
High-dose cytarabine

Access to Document

10.1038/sj.leu.2403766

Cite this

Schlenk, R. F., Germing, U., Hartmann, F., Glasmacher, A., Fischer, I. T., del Valle y Fuentes, F., Götze, K., Pralle, H., Nerl, C., Salwender, H., Grimminger, W., Petzer, A., Hensel, M., Benner, A., Zick, L., Döhner, K., Fröhling, S., & Döhner, H. (2005). High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia, 19(6), 978-983. https://doi.org/10.1038/sj.leu.2403766

@article{477888f1c27649ae956ebc453a975924,

title = "High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia",

abstract = "The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL). Patients (age 16-60 years) received induction therapy according to the AIDA protocol (all-trans retinoic acid, idarubicin) followed by one cycle of ICE (idarubicin, cytarabine, etoposide) and two cycles of HAM (cytarabine 3 g/m2 q12h, days 1-3; mitoxantrone 10 mg/m2, days 2 and 3). From 1995 to 2003, 82 patients were enrolled. In total, 72 patients (88\%) achieved a complete remission, and 10 patients (12\%) died from early/hypoplastic death (ED/HD). A total of 71 patients received at least one cycle of HAM. Relapse-free survival (RFS) and overall survival (OS) after 46 months were 83 and 82\%, respectively. White blood cell count above 10.0 × 109/l at diagnosis and additional chromosomal aberrations were unfavorable prognostic markers for OS, whereas no prognostic markers for RFS were identified including FLT3 mutations. In conclusion, high-dose cytarabine in consolidation therapy for patients with newly diagnosed APL is an effective treatment approach.",

keywords = "Activating FLT3 mutations, Acute promyelocytic leukemia, Additional chromosomal aberrations, High-dose cytarabine",

author = "Schlenk, \{Richard F.\} and U. Germing and F. Hartmann and A. Glasmacher and Fischer, \{I. T.\} and \{del Valle y Fuentes\}, F. and K. G{\"o}tze and H. Pralle and C. Nerl and H. Salwender and W. Grimminger and A. Petzer and M. Hensel and A. Benner and L. Zick and K. D{\"o}hner and S. Fr{\"o}hling and H. D{\"o}hner",

note = "Funding Information: We thank the members of the AML Study Group for providing leukemia specimens and clinical data. This work was supported by Grant 01GI9981 from the Bundesministerium f{\"u}r Bildung und Forschung (Kompetenznetz {\textquoteleft}Akute und chronische Leuk{\"a}mien{\textquoteright}), Germany.",

year = "2005",

month = jun,

doi = "10.1038/sj.leu.2403766",

language = "English",

volume = "19",

pages = "978--983",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "6",

}

Schlenk, RF, Germing, U, Hartmann, F, Glasmacher, A, Fischer, IT, del Valle y Fuentes, F, Götze, K, Pralle, H, Nerl, C, Salwender, H, Grimminger, W, Petzer, A, Hensel, M, Benner, A, Zick, L, Döhner, K, Fröhling, S & Döhner, H 2005, 'High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia', Leukemia, vol. 19, no. 6, pp. 978-983. https://doi.org/10.1038/sj.leu.2403766

TY - JOUR

T1 - High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia

AU - Schlenk, Richard F.

AU - Germing, U.

AU - Hartmann, F.

AU - Glasmacher, A.

AU - Fischer, I. T.

AU - del Valle y Fuentes, F.

AU - Götze, K.

AU - Pralle, H.

AU - Nerl, C.

AU - Salwender, H.

AU - Grimminger, W.

AU - Petzer, A.

AU - Hensel, M.

AU - Benner, A.

AU - Zick, L.

AU - Döhner, K.

AU - Fröhling, S.

AU - Döhner, H.

N1 - Funding Information: We thank the members of the AML Study Group for providing leukemia specimens and clinical data. This work was supported by Grant 01GI9981 from the Bundesministerium für Bildung und Forschung (Kompetenznetz ‘Akute und chronische Leukämien’), Germany.

PY - 2005/6

Y1 - 2005/6

N2 - The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL). Patients (age 16-60 years) received induction therapy according to the AIDA protocol (all-trans retinoic acid, idarubicin) followed by one cycle of ICE (idarubicin, cytarabine, etoposide) and two cycles of HAM (cytarabine 3 g/m2 q12h, days 1-3; mitoxantrone 10 mg/m2, days 2 and 3). From 1995 to 2003, 82 patients were enrolled. In total, 72 patients (88%) achieved a complete remission, and 10 patients (12%) died from early/hypoplastic death (ED/HD). A total of 71 patients received at least one cycle of HAM. Relapse-free survival (RFS) and overall survival (OS) after 46 months were 83 and 82%, respectively. White blood cell count above 10.0 × 109/l at diagnosis and additional chromosomal aberrations were unfavorable prognostic markers for OS, whereas no prognostic markers for RFS were identified including FLT3 mutations. In conclusion, high-dose cytarabine in consolidation therapy for patients with newly diagnosed APL is an effective treatment approach.

AB - The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL). Patients (age 16-60 years) received induction therapy according to the AIDA protocol (all-trans retinoic acid, idarubicin) followed by one cycle of ICE (idarubicin, cytarabine, etoposide) and two cycles of HAM (cytarabine 3 g/m2 q12h, days 1-3; mitoxantrone 10 mg/m2, days 2 and 3). From 1995 to 2003, 82 patients were enrolled. In total, 72 patients (88%) achieved a complete remission, and 10 patients (12%) died from early/hypoplastic death (ED/HD). A total of 71 patients received at least one cycle of HAM. Relapse-free survival (RFS) and overall survival (OS) after 46 months were 83 and 82%, respectively. White blood cell count above 10.0 × 109/l at diagnosis and additional chromosomal aberrations were unfavorable prognostic markers for OS, whereas no prognostic markers for RFS were identified including FLT3 mutations. In conclusion, high-dose cytarabine in consolidation therapy for patients with newly diagnosed APL is an effective treatment approach.

KW - Activating FLT3 mutations

KW - Acute promyelocytic leukemia

KW - Additional chromosomal aberrations

KW - High-dose cytarabine

UR - https://www.scopus.com/pages/publications/20844433082

U2 - 10.1038/sj.leu.2403766

DO - 10.1038/sj.leu.2403766

M3 - Article

C2 - 15843821

AN - SCOPUS:20844433082

SN - 0887-6924

VL - 19

SP - 978

EP - 983

JO - Leukemia

JF - Leukemia

IS - 6

ER -

High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this